RxDoctor Payments Data

Ricky Yu, MD

Internal Medicine · Fargo, NDNPI 1538589429

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Medtronic at 31.6% of the total. Reporting peaked in 2023 at $118 and has fallen 87.3% since, to $15 in 2025.

$306in general payments, 2019–2025

Across 7 payments — averaging $43.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$97
  • Boston Scientific$97
  • Edwards Lifesciences$85
  • Novartis$15
  • Pfizer$13

What the payments were for

  • Food & beverage$306100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic1$97
Boston Scientific2$97
Edwards Lifesciences2$85
Novartis1$15
Pfizer1$13

How this compares

$306 in reported general payments places this provider in the 65th percentile of 159 internal medicine providers in North Dakota.

See all internal medicine providers in North Dakota

Medicare billing

Part B allowed, 2024
$220,431
Medicare patients
2,650
Services billed
6,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban260$258,414
Repatha SureclickEvolocumab175$113,231
FarxigaDapagliflozin Propanediol81$65,888
JardianceEmpagliflozin69$58,755
EntrestoSacubitril/Valsartan34$46,231
XareltoRivaroxaban37$39,679
Praluent PenAlirocumab27$19,677
Metoprolol Succinate850$19,265
Rosuvastatin Calcium735$13,500
Ezetimibe432$10,799
Losartan Potassium543$7,113
Varenicline Tartrate16$6,533
Atorvastatin Calcium435$5,328
NexletolBempedoic Acid11$4,380
Bisoprolol Fumarate86$3,554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$258,414260 claims
NovartisEntresto$15$46,23134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 159 internal medicine providers in North Dakota.

Other internal medicine in Fargo

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →